| Near Infrared Fluorescence Imaging for Bladder Cancer Detection (NCT03058705) | Edward Messing | 2017-11-28 |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma (NCT03291028) | Fox Chase Cancer Center | 2017-11-27 |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (NCT03317158) | Noah Hahn, M.D. | 2017-11-21 |
| A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival (NCT03266900) | University Health Network, Toronto | 2017-11-16 |
| Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers (NCT03413982) | University of Kansas Medical Center | 2017-11-02 |
| Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC (NCT03348969) | Jørgen Bjerggaard Jensen | 2017-11-01 |
| A Study of BCD-135 in Patients With Advanced Solid Tumors (NCT03464032) | Biocad | 2017-10-31 |
| SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly (NCT03362801) | University Hospital, Caen | 2017-10-30 |
| Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer (NCT03327883) | National Cancer Institute (NCI) | 2017-10-26 |
| Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy (NCT03325231) | Swansea University | 2017-10-20 |
| Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers (NCT03134027) | Duke University | 2017-10-19 |
| Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab (NCT03212651) | Gustave Roussy, Cancer Campus, Grand Paris | 2017-10-17 |
| Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer (NCT03150836) | Terence Friedlander, MD | 2017-10-01 |
| Chemoradiotherapy for Recurrent T1G3 Bladder Cancer (NCT03274284) | Assiut University | 2017-10-01 |
| Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia (NCT03007771) | Washington University School of Medicine | 2017-09-30 |
| Investigation of Sugammadex in Outpatient Urological Procedures (NCT03138967) | M.D. Anderson Cancer Center | 2017-09-18 |
| The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting (NCT03232541) | Västernorrland County Council, Sweden | 2017-09-01 |
| Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. (NCT03245736) | Seagen Inc. | 2017-08-23 |
| A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) (NCT03224182) | Spectrum Pharmaceuticals, Inc | 2017-08-04 |
| Project HERO: Health Empowerment & Recovery Outcomes (NCT03345563) | Rutgers, The State University of New Jersey | 2017-07-31 |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch (NCT02643043) | Matthew Milowsky, MD | 2017-07-26 |
| Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer (NCT02662062) | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 2017-07-11 |
| Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NCT03171025) | University of Utah | 2017-07-10 |
| Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy (NCT03106610) | M.D. Anderson Cancer Center | 2017-07-07 |
| Mass Spectrometry in Single Bladder Cancer Cells (NCT03639090) | University of Oklahoma | 2017-07-01 |
| Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients (NCT03739177) | Animated Dynamics, Inc. | 2017-06-22 |
| QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (NCT03022825) | ImmunityBio, Inc. | 2017-06-02 |
| Lifestyle Change for Better Health (NCT03286699) | University of Pittsburgh | 2017-06-01 |
| Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment (NCT01489813) | Emory University | 2017-05-19 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (NCT03125200) | ADC Therapeutics S.A. | 2017-05-18 |
| Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder (NCT02845323) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-05-16 |
| A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) (NCT03121768) | Mansoura University | 2017-05-15 |
| Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders (NCT03147599) | Mansoura University | 2017-05-15 |
| Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage (NCT03138837) | Mansoura University | 2017-05-15 |
| Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients (NCT03156244) | UNC Lineberger Comprehensive Cancer Center | 2017-05-08 |
| Transurethral En Bloc Versus Standard Resection of Bladder Tumour (NCT02993211) | Chinese University of Hong Kong | 2017-04-18 |
| Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy (NCT03307200) | University Hospital, Ghent | 2017-04-03 |
| Multi Institutional Study in Patient Presenting With Hematuria (NCT03122964) | MDx Health | 2017-03-31 |
| Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer (NCT03063125) | University of Kansas Medical Center | 2017-03-31 |
| Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia (NCT05397262) | University of Erlangen-Nürnberg Medical School | 2017-03-29 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (NCT02788201) | National Cancer Institute (NCI) | 2017-03-27 |
| Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1 (NCT03007719) | Lawrence Fong | 2017-03-07 |
| Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy (NCT03049410) | University College, London | 2017-03-01 |
| Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy (NCT03147586) | Mansoura University | 2017-03-01 |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder (NCT02901548) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| Respiratory Measurement Using Infrared Camera and Respiratory Volume Monitor (ExSpiron 1Xi) for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia (NCT02993497) | Yonsei University | 2017-02-05 |
| The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation (NCT03058757) | National Cancer Center, Korea | 2017-02-01 |
| Early Versus Late FDG-PET/CT in Bladder Cancer (NCT03065725) | Jørgen Bjerggaard Jensen | 2017-02-01 |
| Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis (NCT01710293) | VA Office of Research and Development | 2017-01-27 |
| Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors (NCT02966691) | Vitadx | 2017-01-24 |
| Urine-DNA Biomarkers in Detecting Bladder Cancer (NCT03066310) | Xiangya Hospital of Central South University | 2017-01-17 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma (NCT02887248) | SCRI Development Innovations, LLC | 2017-01-12 |
| Protocol of the Italian Radical Cystectomy Registry (NCT04228198) | University of Roma La Sapienza | 2017-01-01 |
| Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment (NCT02695121) | AstraZeneca | 2017-01-01 |
| Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy (NCT03193788) | Asan Medical Center | 2017-01-01 |
| A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer (NCT02951078) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2017-01-01 |
| A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer (NCT03193528) | Cedars-Sinai Medical Center | 2016-12-30 |
| A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer (NCT03193541) | Cedars-Sinai Medical Center | 2016-12-30 |
| A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer (NCT03193515) | Cedars-Sinai Medical Center | 2016-12-30 |
| A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers (NCT02643303) | Ludwig Institute for Cancer Research | 2016-12-28 |
| A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (NCT02999672) | Hoffmann-La Roche | 2016-12-23 |
| Image-Guided Gynecologic Brachytherapy (NCT02993900) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-12-15 |
| Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract (NCT02925533) | Mark Pomerantz, MD | 2016-12-14 |
| Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer (NCT02885974) | Baylor College of Medicine | 2016-12-01 |
| Complications of Transurethral Resection of the Bladder Tumour (NCT03029663) | Medical University of Warsaw | 2016-12-01 |
| Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer (NCT03125460) | Cepheid | 2016-12-01 |
| Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors (NCT02897375) | Emory University | 2016-10-24 |
| Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) (NCT02704832) | Institut Bergonié | 2016-09-30 |
| To Detect the Sensitivity of the UroMark Assay (NCT02781428) | University College, London | 2016-09-26 |
| Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914) | Incyte Corporation | 2016-09-14 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217) | University Health Network, Toronto | 2016-09-01 |
| RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) (NCT02471495) | Medical Enterprises Europe B.V. | 2016-09-01 |
| Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy (NCT03052504) | Jørgen Bjerggaard Jensen | 2016-09-01 |
| The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma (NCT02700464) | Nucleix Ltd. | 2016-09-01 |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma (NCT03296306) | Asan Medical Center | 2016-09-01 |
| Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (NCT02852564) | Eugene Lee, MD | 2016-08-01 |
| Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates (NCT04768894) | Saglik Bilimleri Universitesi | 2016-08-01 |
| Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection (NCT02800473) | Institut de Cancérologie de Lorraine | 2016-07-04 |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (NCT02576665) | Tocagen Inc. | 2016-07-01 |
| Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry (NCT02852252) | University of Pennsylvania | 2016-07-01 |
| A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors (NCT02886897) | Sun Yat-sen University | 2016-07-01 |
| Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients (NCT02811952) | Carmel Medical Center | 2016-06-23 |
| Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants (NCT02792192) | Hoffmann-La Roche | 2016-06-13 |
| Bladder Cancer Adjuvant Radiotherapy Trial (NCT02951325) | Tata Memorial Centre | 2016-06-02 |
| A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer (NCT02753309) | The University of Texas Health Science Center at San Antonio | 2016-06-01 |
| Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers (NCT02648178) | Dartmouth-Hitchcock Medical Center | 2016-06-01 |
| Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (NCT02886026) | University Hospital Bispebjerg and Frederiksberg | 2016-06-01 |
| Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy (NCT02690558) | UNC Lineberger Comprehensive Cancer Center | 2016-05-01 |
| Observation Versus Immediate Surgery of Low Risk Bladder Cancer (NCT02700724) | Vanderbilt University Medical Center | 2016-04-01 |
| Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710 (NCT02756637) | Abramson Cancer Center at Penn Medicine | 2016-04-01 |
| Detecting Bladder Cancer Using the UroMark Test. (NCT02676180) | University College, London | 2016-03-30 |
| The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer (NCT02716623) | University of Kansas Medical Center | 2016-03-01 |
| Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) (NCT02625961) | Merck Sharp & Dohme LLC | 2016-02-10 |
| Photodynamic Diagnosis (PDD) in Flexible Cystoscopy (NCT02660190) | Jørgen Bjerggaard Jensen | 2016-02-01 |
| Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers (NCT02675829) | Memorial Sloan Kettering Cancer Center | 2016-02-01 |
| Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder (NCT02662309) | Queen Mary University of London | 2016-02-01 |
| BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (NCT02657486) | Memorial Sloan Kettering Cancer Center | 2016-01-06 |
| Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy (NCT02145390) | University of Miami | 2016-01-05 |
| Enzalutamide for Bladder Cancer Chemoprevention (NCT02605863) | University of Rochester | 2016-01-01 |
| Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma (NCT02647112) | Nucleix Ltd. | 2015-12-01 |